Enzo Biochem (ENZ) Getting Somewhat Favorable News Coverage, Report Shows
Media coverage about Enzo Biochem (NYSE:ENZ) has trended somewhat positive this week, according to Alpha One Sentiment Analysis. The research firm, a unit of Accern, scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Alpha One ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Enzo Biochem earned a media sentiment score of 0.24 on Alpha One’s scale. Alpha One also gave news articles about the medical research company an impact score of 62 out of 100, indicating that recent press coverage is somewhat likely to have an effect on the company’s share price in the near future.
Here are some of the media stories that may have impacted Alpha One Sentiment Analysis’s rankings:
- Zacks: Enzo Biochem, Inc. (ENZ) Given $8.00 Average Target Price by Analysts (americanbankingnews.com)
- Top 5 Biotech Stocks as of June 2017 (JAZZ, ENZ) (investopedia.com)
- Enzo Biochem, Inc. :ENZ-US: Earnings Analysis: Q3, 2017 By the Numbers : June 12, 2017 (finance.yahoo.com)
- Enzo Biochem, Inc.: Strong price momentum but will it sustain? (finance.yahoo.com)
Shares of Enzo Biochem (ENZ) traded up 0.19% during mid-day trading on Friday, hitting $10.51. 334,321 shares of the company traded hands. The firm has a 50-day moving average price of $9.26 and a 200 day moving average price of $7.77. The firm has a market cap of $487.74 million, a price-to-earnings ratio of 14.74 and a beta of 0.91. Enzo Biochem has a 52-week low of $4.88 and a 52-week high of $10.85.
Enzo Biochem (NYSE:ENZ) last announced its quarterly earnings data on Monday, March 13th. The medical research company reported ($0.02) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.04) by $0.02. The firm had revenue of $26.26 million during the quarter, compared to analyst estimates of $26.10 million. Enzo Biochem had a negative return on equity of 5.13% and a net margin of 31.57%. During the same period last year, the company earned ($0.07) earnings per share. Equities research analysts anticipate that Enzo Biochem will post ($0.07) EPS for the current fiscal year.
Separately, Zacks Investment Research cut shares of Enzo Biochem from a “buy” rating to a “hold” rating in a research note on Tuesday, May 16th.
Enzo Biochem Company Profile
Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.
Receive News & Stock Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related stocks with our FREE daily email newsletter.